Assembly Biosciences to Present Phase 1a Safety Data on Oral HDV Entry Inhibitor ABI-6250
Assembly Biosciences will present topline Phase 1a safety, pharmacokinetic and pharmacodynamic data on its oral HDV entry inhibitor ABI-6250 at the EASL Congress in Barcelona May 27–30, 2026. These interim results support advancing ABI-6250 directly into a Phase 2 study by year-end as the only oral HDV entry inhibitor in development.
1. EASL Congress Presentation
Assembly Biosciences will present topline results from its randomized, blinded Phase 1a study of ABI-6250 at the European Association for the Study of the Liver Congress in Barcelona, May 27–30, 2026. The poster (WED-579) will be delivered by Edward J. Gane, MD, detailing safety, pharmacokinetic and pharmacodynamic activity following single and multiple doses in healthy participants.
2. ABI-6250 Profile and Next Steps
ABI-6250 is a first-in-class oral hepatitis D virus entry inhibitor designed to block viral entry into hepatocytes. As the only oral HDV entry inhibitor in clinical development, these interim Phase 1a data support Assembly Biosciences’ plan to advance directly into a Phase 2 efficacy study by year-end 2026.